Document Type
Plan B - Open Access
Award Date
2022
Degree Name
Master of Science (MS)
Department
Biology and Microbiology
First Advisor
Greg Heiberger
Abstract
Alzheimer’s Disease (AD) is a degenerative brain disease caused by cell damage leading to brain changes such as amyloid plaques and neurofibrillary tangles. Alois Alzheimer was a clinical psychiatrist and neuroanatomist in Germany who first discovered Alzheimer’s Disease through microscopic viewing of Auguste D’s brain. Through more research following Dr. Alzheimer’s death, they began to stage AD. The six stages are: pre-clinical, mild, moderate, moderately severe, severe, and very severe. The current treatments approved by the FDA work to slow the progression of AD, rather than modify the disease. There are currently three Disease-Modifying Biologic clinical-trial drugs on the market for AD: Gantenerumab, Lecanemab, and Solanezumab, each with completed phase one and phase two trials and several phase three trials in progress.
Number of Pages
31
Publisher
South Dakota State University
Rights
© 2022 Haley Jahnke
Recommended Citation
Jahnke, Haley, "Alzheimer’s Disease: An Overview and Current Phase 3 Disease-Modifying Biologic Treatments" (2022). Biology and Microbiology Graduate Students Plan B Research Projects. 43.
https://openprairie.sdstate.edu/biomicro_plan-b/43